Stories
Dr Reddy's Secures DCGI Approval for Esophageal Cancer Drug Zytorvi
N
News18•21-10-2026, 11:30
Dr Reddy's Secures DCGI Approval for Esophageal Cancer Drug Zytorvi
- •Dr Reddy's Laboratories received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.
- •The drug is approved for use in combination with cisplatin and paclitaxel as a first-line treatment for adult patients.
- •ESCC accounts for approximately 80 percent of all esophageal cancer cases across India.
- •The approval is backed by Phase 3 JUPITER-06 trial results showing a 42 percent reduction in the risk of disease progression or death.
- •Dr Reddy's holds commercialisation rights for toripalimab across 21 countries through an agreement with Junshi Biosciences.
Key Questions Answered
Dr Reddy's Laboratories received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab) to expand access to first-line immunotherapy for advanced esophageal squamous cell carcinoma.
The approval was backed by Phase 3 JUPITER-06 trial results showing a 42 percent risk reduction in disease or death when combined with chemotherapy, yielding a median overall survival of 17.7 months compared to 12.9 months for chemotherapy alone.
Dr Reddy's holds commercialisation rights for toripalimab across 21 countries following a 2023 agreement with Junshi Biosciences.
